Glucocerebrosidase mutations confer a greater risk of dementia during Parkinson's disease course
The DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Abstract
Mutations in the glucocerebrosidase gene are associated with Parkinson's disease and Lewy body dementia. However, whether these alterations have any effect on the clinical course of Parkinson's disease is not clear. The glucocerebrosidase coding region was fully sequenced in 225 Parkinson's disease patients, 17 pathologically confirmed Lewy body dementia patients, and 186 controls from Spain. Twenty‐two Parkinson's disease patients (9.8%) and 2 Lewy body dementia patients (11.8%) carried mutations in the glucocerebrosidase gene, compared with only 1 control (0.5%); P = .016 and P = .021 for Parkinson's disease and Lewy body dementia, respectively. The N370S and the L444P mutations represented 50% of the alterations. Two novel variants, L144V and S488T, and 7 previously described alterations were also found. Alterations in glucocerebrosidase were associated with a significant risk of dementia during the clinical course of Parkinson's disease (age at onset, years of evolution, and sex‐adjusted odds ratio, 5.8; P = .001). Mutation carriers did not show worse motor symptoms, had good response to L‐dopa, and tended to present the intermediate parkinsonian phenotype. Our findings suggest that mutations in the glucocerebrosidase gene not only increase the risk of both Parkinson's disease and Lewy body dementia but also strongly influence the course of Parkinson's disease with respect to the appearance of dementia. © 2011 Movement Disorder Society
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A method and server for predicting damaging missense mutations.
Adzhubei, I. A., Schmidt, S., Peshkin, L., Ramensky, V. E., Gerasimova, A., Bork, P., Kondrashov, A. S., & Sunyaev, S. R. (2010) · Nature Methods · doi:10.1038/nmeth0410-248 · Cited by 13,194 · cited 1×
“edu/pph2/) was used to predict the functionality of novel mutations.(30) HumDiv-trained PolyPhen-2 scores were used.”
MethodParkinsonism: onset, progression, and mortality
Hoehn, M. M., & Yahr, M. D. (1967) · Neurology · doi:10.1212/wnl.17.5.427 · Cited by 12,107 · cited 1×
“Motor symptoms and disease severity were assessed according to the Unified Parkinson’s Disease Rating Scale (UPDRS)(22) and Hoehn & Yahr scores.(23) Average UPDRS and Hoehn & Yahr scores at the moment of blood withdrawal were 30 6 14 and 2.”
MethodHughes, A. J., Daniel, S. E., Kilford, L., & Lees, A. J. (1992) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.55.3.181 · Cited by 10,378
A New Clinical Scale for the Staging of Dementia
Hughes, C. P., Berg, L., Danziger, W., Coben, L. A., & Martin, R. L. (1982) · British Journal of Psychiatry · doi:10.1192/bjp.140.6.566 · Cited by 7,056
Diagnosis and management of dementia with Lewy bodies: Third report of the DLB consortium
McKeith, I. G., Dickson, D. W., Lowe, J., Emre, M., O'Brien, J. T., Feldman, H., Cummings, J., Duda, J. E., Lippa, C., Perry, E. K., et al. (2005) · Neurology · doi:10.1212/01.wnl.0000187889.17253.b1 · Cited by 5,069
Self-citationMulticenter Analysis of Glucocerebrosidase Mutations in Parkinson's Disease
Sidransky, E., Nalls, M. A., Aasly, J. O., Aharon-Peretz, J., Annesi, G., Barbosa, E. R., Bar-Shira, A., Berg, D., Bras, J., Brice, A., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0901281 · Cited by 2,135
Mazzulli, J. R., Xu, Y.-H., Sun, Y., Knight, A. L., McLean, P. J., Caldwell, G. A., Sidransky, E., Grabowski, G. A., & Krainc, D. (2011) · Cell · doi:10.1016/j.cell.2011.06.001 · Cited by 1,341
Pathogenic Lysosomal Depletion in Parkinson's Disease
Dehay, B., Bové, J., Rodríguez-Muela, N., Perier, C., Recasens, A., Boya, P., & Vila, M. (2010) · The Journal of Neuroscience · doi:10.1523/jneurosci.1920-10.2010 · Cited by 825
Glucocerebrosidase mutations in clinical and pathologically proven Parkinson’s disease
Neumann, J., Bras, J., Deas, E., O'Sullivan, S. S., Parkkinen, L., Lachmann, R. H., Li, A., Holton, J., Guerreiro, R., Paudel, R., et al. (2009) · Brain · doi:10.1093/brain/awp044 · Cited by 696
Self-citationVogiatzi, T., Xilouri, M., Vekrellis, K., & Stefanis, L. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m801992200 · Cited by 683
Cited by
Cognitive decline in Parkinson disease
Aarsland, D., Creese, B., Politis, M., Chaudhuri, K. R., ffytche, D. H., Weintraub, D., & Ballard, C. (2017) · Nature Reviews Neurology · doi:10.1038/nrneurol.2017.27 · Cited by 1,027
The link between the GBA gene and parkinsonism
Sidransky, E., & Lopez, G. (2012) · The Lancet Neurology · doi:10.1016/s1474-4422(12)70190-4 · Cited by 583
Cognitive impairment in patients with Parkinson's disease: diagnosis, biomarkers, and treatment
Svenningsson, P., Westman, E., Ballard, C., & Aarsland, D. (2012) · The Lancet Neurology · doi:10.1016/s1474-4422(12)70152-7 · Cited by 499
A Multicenter Study of Glucocerebrosidase Mutations in Dementia With Lewy Bodies
Nalls, M. A., Duran, R., Lopez, G., Kurzawa-Akanbi, M., McKeith, I. G., Chinnery, P. F., Morris, C. M., Theuns, J., Crosiers, D., Cras, P., et al. (2013) · JAMA Neurology · doi:10.1001/jamaneurol.2013.1925 · Cited by 439
Self-citationSurvival and dementia in GBA ‐associated Parkinson's disease: The mutation matters
Cilia, R., Tunesi, S., Marotta, G., Cereda, E., Siri, C., Tesei, S., Zecchinelli, A. L., Canesi, M., Mariani, C. B., Meucci, N., et al. (2016) · Annals of Neurology · doi:10.1002/ana.24777 · Cited by 406
Are dementia with Lewy bodies and Parkinson’s disease dementia the same disease?
Jellinger, K. A., & Korczyn, A. D. (2018) · BMC Medicine · doi:10.1186/s12916-018-1016-8 · Cited by 385
Differential effects of severe vs mild GBA mutations on Parkinson disease
Gan-Or, Z., Amshalom, I., Kilarski, L. L., Bar-Shira, A., Gana-Weisz, M., Mirelman, A., Marder, K., Bressman, S., Giladi, N., & Orr-Urtreger, A. (2015) · Neurology · doi:10.1212/wnl.0000000000001315 · Cited by 364
Winder-Rhodes, S. E., Evans, J. R., Ban, M., Mason, S. L., Williams-Gray, C. H., Foltynie, T., Duran, R., Mencacci, N. E., Sawcer, S. J., & Barker, R. A. (2013) · Brain · doi:10.1093/brain/aws318 · Cited by 290
Dementia with Lewy bodies and Parkinson’s disease-dementia: current concepts and controversies
Jellinger, K. A. (2018) · Journal of Neural Transmission · doi:10.1007/s00702-017-1821-9 · Cited by 264
The olfactory bulb as the entry site for prion-like propagation in neurodegenerative diseases
Rey, N. L., Wesson, D. W., & Brundin, P. (2018) · Neurobiology of Disease · doi:10.1016/j.nbd.2016.12.013 · Cited by 257
“Finally, individuals with heterozygous GBA mutations (Doty, 2012b; Goker-Alpan et al., 2008; Saunders-Pullman et al., 2010), who have a six-fold greater risk of PD (Setó-Salvia et al., 2011), exhibit impaired olfaction after the appearance of motor deficits.”
Almeida, M. R., Macário, M. C., Ramos, L., Baldeiras, I., Ribeiro, M. H., & Santana, I. (2016) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2016.02.019 · Cited by 125
Exploring the link between GBA1 mutations and Dementia with Lewy bodies, A mini-review
Gaubert, S., Hourregue, C., Mouton-Liger, F., Millot, P., Franco, M., Amar-Bouaziz, E., Aarsland, D., Hugon, J., & Paquet, C. (2022) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2022.104856 · Cited by 26
Metadata
- Authors
- Setó‐Salvia, N., Pagonabarraga, J., Houlden, H., Pascual‐Sedano, B., Dols‐Icardo, O., Tucci, A., Paisán‐Ruiz, C., Campolongo, A., Antón‐Aguirre, S., Martín, I., Muñoz, L., Bufill, E., Vilageliu, L., Grinberg, D., Cozar, M., Blesa, R., Lleó, A., Hardy, J., Kulisevsky, J., & Clarimón, J.
- Venue
- Movement Disorders
- Publisher
- Wiley
- Published
- 2011-12-15
- Volume
- 27
- Issue
- 3
- Pages
- 393-399
- ISSN
- 0885-3185 (ISSN-L)
- 1531-8257
- OpenAlex
- W2030090069
- Cited by
- 155
- References
- 11
- FWCI
- 5.78
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.